Clinical Trials Logo

Renal Impairment clinical trials

View clinical trials related to Renal Impairment.

Filter by:

NCT ID: NCT01575925 Completed - Multiple Myeloma Clinical Trials

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

POM Renal
Start date: June 1, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and impaired renal function.

NCT ID: NCT01558323 Completed - Renal Impairment Clinical Trials

Pharmacokinetics of LCQ908 in Patients With Renal Impairment

Start date: May 2012
Phase: Phase 1
Study type: Interventional

This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of renal impairment to healthy subjects

NCT ID: NCT01555008 Completed - Clinical trials for Type 2 Diabetes Mellitus

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Start date: March 2012
Phase: Phase 1
Study type: Interventional

This Phase 1 study is intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of LX4211 following once daily oral administration in subjects with type 2 diabetes mellitus (T2DM) and moderate to severe renal impairment.

NCT ID: NCT01526746 Completed - Renal Impairment Clinical Trials

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Start date: February 2012
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood of individuals with severe renal impairment compared to individuals who have normal renal function. The safety and tolerability of tasimelteon will also be assessed throughout this study.

NCT ID: NCT01504165 Completed - Renal Impairment Clinical Trials

Pharmacokinetics in Subjects With Renal Impairment

Start date: January 2012
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized, parallel-group, mono-center, single intravenous dose, Phase I trial to investigate the Pharmacokinetic (PK) and safety of cilengitide in subjects with different grades of renal impairment as compared to subjects with normal renal function.

NCT ID: NCT01464931 Completed - Renal Impairment Clinical Trials

Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

Start date: November 2011
Phase: Phase 1
Study type: Interventional

The primary objective was to evaluate the incidence of clinically significant hypocalcemia following multiple 120 mg subcutaneous doses of denosumab in patients with severe chronic kidney disease (CKD) and CKD on dialysis

NCT ID: NCT01459250 Completed - Renal Impairment Clinical Trials

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

Start date: March 2011
Phase: Phase 1
Study type: Interventional

This study will assess the pharmacokinetics, safety and tolerability of a single dose of AGO178C in subjects with mild, moderate, severe renal impairment and end-stage renal disease with that in healthy matched control subjects.

NCT ID: NCT01452828 Completed - Renal Impairment Clinical Trials

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Start date: October 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the single dose pharmacokinetics (PK) and safety of TR701 FA in subjects with advance renal impairment.

NCT ID: NCT01443429 Completed - Renal Impairment Clinical Trials

A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment

Start date: August 2011
Phase: Phase 1
Study type: Interventional

The PK and safety profiles to be examined following a single oral administration of TRK-100STP (120 μg) under fasting conditions to patients with renal impairment and to subjects with normal renal function.

NCT ID: NCT01419041 Completed - Renal Impairment Clinical Trials

A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

Start date: November 2011
Phase: Phase 1
Study type: Interventional

The present study is being conducted to evaluate whether or not severe renal impairment has an effect on crizotinib Pharmacokinetics.